NCT04197492View on ClinicalTrials.gov

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Malignant Glioma
Interventions
RADIATION

Hypofractionated Stereotactic Radiotherapy

Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)

DRUG

Anlotinib

Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.

Trial Locations (1)

200040

CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER

NCT04197492 - Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | Biotech Hunter | Biotech Hunter